An observational study in Supraventricular Tachycardia (SVT), sponsored by University of Iowa. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by University of Iowa · Observational
Supraventricular tachycardia (SVT) is a dysrhythmia characterized rapid heart rate, typically with rapid onset. SVT accounts for over 50,000 emergency department visits per year. Of patients with regular, narrow-complex SVT, the mainstay of therapy includes adenosine and diltiazem. Adenosine is recommend by American and European guidelines as first-line therapy, however adenosine carries unique side effects that are potentially distressing to patients, including: "feeling of impending death or doom", flushing, anxiety, shortness of breath, and chest discomfort. Diltiazem does not carry this side effect profile, but has typically been reserved as second-line treatment due to side effects of low blood pressure associated with this class of medications. Diltiazem and adenosine have not been well studied head-to-head to compare safety and efficacy of their treatment for SVT. The purpose of this study is to evaluate safety and efficacy of adenosine and diltiazem for SVT in the ED (as completed through chart review of specific patient-level outcomes) and capture patient and clinician perspectives of medication satisfaction (through administration of questionnaires).
73 studies on the registry are indexed under Tachycardia, Supraventricular; 22 are open to participants now.
This study's planned enrollment of 100 is above the median of 87 across 28 observational studies indexed under Tachycardia, Supraventricular.
Browse Tachycardia, Supraventricular studies →University of Iowa is the lead sponsor of 279 studies on the registry; 33 are open to participants now.
Of its 45 completed or terminated interventional studies of FDA-regulated products, 40 (89%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult patients (≥18 years of age) treated for SVT in the ED. The investigators will screen a convenience sample of adult patients presenting with stable SVT in the ED for study eligibility while study investigators (most often emergency medicine clinical pharmacists) are available to enroll participants and administer study questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: IV adenosine
Drug: IV diltiazem
Patients will not be randomized to intervention but will be categorized based on the exposure of IV adenosine for treatment of SVT received prior to study enrollment
Patients will not be randomized to intervention but will be categorized based on the exposure of IV diltiazem for treatment of SVT received prior to study enrollment
Patient satisfaction with SVT treatment
Patient satisfaction with treatment will be assessed using a Likert scale questionnaire of 1-5. Participants will indicate their satisfaction with treatment by indicating a score of 1-5, 1 being "not at all satisfied" and 5 being "extremely satisfied".
Time frame: Primary outcome will be assessed during ED visit
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Jun 2027, 26 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tachycardia, Supraventricular →